<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14024">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924324</url>
  </required_header>
  <id_info>
    <org_study_id>16-1417</org_study_id>
    <nct_id>NCT02924324</nct_id>
  </id_info>
  <brief_title>Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients</brief_title>
  <official_title>Local Analgesia Use for Bone Marrow Procedures for Pediatric Neuroblastoma Patients: a Prospective Randomized Cross-over Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify whether or not the addition of a numbing medicine
      that is injected directly into the site of the bone marrow procedure can reduce pain and the
      use of opioid pain medication after bone marrow procedures. The addition of this medicine,
      called ropivacaine, is the experimental part of this study. This is the first time
      ropivacaine will be directly injected into the bone marrow site at MSKCC Pediatrics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients requiring post-procedural opioid analgesia</measure>
    <time_frame>within 24 hours (+/- 4 hours) post procedure</time_frame>
    <description>Post-operative pain reported on the Wong-Baker FACES® Pain Rating Scale (converted to scale of 0-10) will be measured</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>propofol alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1st Bone Marrow procedure (BM) Intervention A: propofol alone. Crossover for second BM procedure propofol &amp; ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol and ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st BM procedure: Intervention B: propofol &amp; ropivacaine. Crossover for second BM procedure propofol alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>propofol</intervention_name>
    <arm_group_label>propofol alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <arm_group_label>propofol and ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Wong-Baker FACES® Pain Rating Scale</intervention_name>
    <description>Nurses will record patient-reported pain scores.</description>
    <arm_group_label>propofol alone</arm_group_label>
    <arm_group_label>propofol and ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Post-procedural quality of life (QOL)</intervention_name>
    <arm_group_label>propofol alone</arm_group_label>
    <arm_group_label>propofol and ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of neuroblastoma as defined by the International Neuroblastoma Risk Group
             Staging System (INRGSS)22

          -  3 - 18 years of age

          -  Patient has had prior bone marrow procedures

          -  English speaking

        Exclusion Criteria:

          -  History of allergy to investigational agent: ropivacaine or other amino amide
             analgesics

          -  History of allergy to standard agent: propofol

          -  Chronic daily opioid requirement

          -  Lansky/Karnofsky Score &lt; 60

          -  Inability to comply with protocol requirements including refusal to forego
             pre-procedural opioid use

          -  Patient is receiving additional potentially painful interventions (e.g. central line
             insertion/removal) concurrent with the bone marrow procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Dingeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert S Dingeman, MD</last_name>
    <phone>212-639-6551</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Basu, MD, PhD</last_name>
    <phone>212-639-5204</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S Dingeman, MD</last_name>
      <phone>212-639-6551</phone>
    </contact>
    <contact_backup>
      <last_name>Ellen Basu, MD, PhD</last_name>
      <phone>212-639-5204</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert S Dingeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 21, 2016</lastchanged_date>
  <firstreceived_date>October 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>local Injection</keyword>
  <keyword>pain Medication</keyword>
  <keyword>propofol</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>16-1417</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
